| scholarly article | Q13442814 |
| P50 | author | Jan A. Staessen | Q37390604 |
| P2093 | author name string | Liu G | |
| Liu L | |||
| Wang JG | |||
| Gong L | |||
| P433 | issue | 12 Pt 1 | |
| P921 | main subject | People's Republic of China | Q148 |
| arterial hypertension | Q41861 | ||
| placebo | Q269829 | ||
| patient | Q181600 | ||
| systole | Q496359 | ||
| collaboration | Q1145523 | ||
| systolic hypertension | Q7663896 | ||
| P304 | page(s) | 1823-1829 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Journal of Hypertension | Q6295318 |
| P1476 | title | Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. | |
| P478 | volume | 16 |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q42849832 | 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension |
| Q51821764 | 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. |
| Q64080237 | 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension |
| Q37656201 | 7th Brazilian Guideline of Arterial Hypertension: Chapter 11 - Arterial Hypertension in the elderly |
| Q34328239 | A critique of hypertension treatment trials and of their evaluation |
| Q34738073 | A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker |
| Q37810906 | Aging and hypertension |
| Q43208657 | Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial |
| Q43874847 | Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension |
| Q40084348 | An epidemiological survey of stroke among rural Chinese adults results from the Liaoning province |
| Q38542774 | Antihypertensive Treatment in the Elderly and Very Elderly: Always "the Lower, the Better?" |
| Q48151925 | Antihypertensive drug treatment: the real-life challenge. |
| Q56658918 | Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials |
| Q80810329 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study |
| Q33768748 | Antihypertensive therapy in the prevention of stroke: what, when and for whom? |
| Q36991767 | Arterial Stiffening in Perspective: Advances in Physical and Physiological Science Over Centuries |
| Q40057422 | Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. |
| Q44295781 | Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials |
| Q35545480 | Benefits of blood pressure reduction in elderly patients |
| Q35124979 | Blood Pressure and Lipid Lowering in the Prevention of Stroke: A Note to Neurologists |
| Q33588483 | Blood pressure and ageing |
| Q26996563 | Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses |
| Q37593677 | Blood pressure control in the elderly: can you have too much of a good thing? |
| Q34507164 | Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis |
| Q24246379 | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia |
| Q24240206 | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia |
| Q57085413 | Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis |
| Q64977297 | Blood pressure targets for hypertension in patients with type 2 diabetes. |
| Q36783875 | Blood pressure: the lower, the better: the con side |
| Q33797387 | British Hypertension Society guidelines for hypertension management 1999: summary |
| Q37113512 | Calcium antagonists and renal failure progression. |
| Q34849534 | Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension |
| Q24236584 | Calcium channel blockers versus other classes of drugs for hypertension |
| Q34633329 | Carcinogenicity of antihypertensive therapy |
| Q36834034 | Cardiovascular diseases in China |
| Q39068770 | Cardiovascular diseases in China: Current status and future perspectives |
| Q43782892 | Cardiovascular protection and blood pressure reduction: a meta-analysis |
| Q38245562 | Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension. |
| Q45227909 | Case studies in hypertension. Dihydropyridine/nondihydropyridine calcium channel blocker combination therapy |
| Q38071014 | Characteristics of hypertension in Chinese and their relevance for the choice of antihypertensive drugs |
| Q38030481 | Characteristics of hypertension in the Chinese population |
| Q26851095 | Chinese Hypertension Guidelines |
| Q47910182 | Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks |
| Q35079837 | Clinical trial experience around the globe: focus on calcium-channel blockers. |
| Q74299110 | Clinical trials in isolated systolic hypertension |
| Q46883368 | Closing remarks: current position of calcium channel antagonists in hypertension--the role of manidipine |
| Q36941748 | Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. |
| Q35166368 | Current treatment of patients with hypertension: therapeutic implications of INSIGHT. |
| Q74299043 | Current trials |
| Q35187888 | Drug therapy of heart failure in the elderly |
| Q93176470 | Effect Modification by Age on the Benefit or Harm of Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review and Meta-analysis |
| Q37556484 | Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. |
| Q36572955 | Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk |
| Q55260712 | Effects of a low salt diet on isolated systolic hypertension: A community-based population study. |
| Q58209727 | Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes |
| Q33739104 | Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study |
| Q46721149 | Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years |
| Q26830725 | Elderly hypertensives: how are they different? |
| Q30774952 | Emerging data on calcium-channel blockers: the COHORT study |
| Q54598217 | Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. |
| Q46424869 | Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain |
| Q38231349 | Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials |
| Q37738335 | Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease |
| Q77480657 | Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy |
| Q91576294 | Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective |
| Q34090645 | First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents |
| Q36085768 | Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence |
| Q37004035 | Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril |
| Q35170117 | Has the role of calcium channel blockers in treating hypertension finally been defined? |
| Q37567490 | Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. |
| Q38022713 | Heart failure in hypertension: prevention and treatment |
| Q34714754 | High blood pressure in the geriatric population: treatment considerations |
| Q61456037 | Hipertensión arterial: cuanto más la conocemos peor la tratamos |
| Q24799416 | How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2) |
| Q35566921 | Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis |
| Q55889453 | Hypertension |
| Q26745496 | Hypertension and Related Cardiovascular Disease Burden in China |
| Q36814866 | Hypertension and kidney protection in the elderly: what is the evidence in 2007? |
| Q26992100 | Hypertension criterion for stroke prevention--to strengthen the principle of individualization in guidelines |
| Q46926321 | Hypertension in african americans aged 60 to 79 years: statement from the international society of hypertension in blacks |
| Q34076199 | Hypertension in patients presenting with stroke |
| Q74785389 | Hypertension in the elderly |
| Q36102223 | Hypertension in the elderly: a Japanese perspective |
| Q98770748 | Hypertension management in older adults |
| Q38129267 | Hypertension-related stroke prevention in the elderly |
| Q43844335 | Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke |
| Q75287363 | Impact of the high-risk and mass strategies on hypertension control and stroke mortality in primary health care |
| Q33697546 | Implications of the Systolic Hypertension in China trial |
| Q34273640 | Improved outcomes with antihypertensive medication in the elderly with isolated systolic hypertension |
| Q33594293 | Incidence and predictors of hypertension among rural Chinese adults: results from Liaoning province |
| Q34028278 | Intensive antihypertensive treatment to the new lower blood pressure targets |
| Q37414790 | Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor? |
| Q34775477 | Is hypertension a leading cause of heart failure in Chinese? |
| Q42332382 | Isolated systolic hypertension as a treatable risk factor |
| Q52900962 | Isolated systolic hypertension. An independent disease |
| Q77700949 | Isolated systolic hypertension: an important cardiovascular risk factor |
| Q30767703 | Isolated systolic hypertension: data on a cohort of young subjects from a French working population (IHPAF). |
| Q34622234 | Large therapeutic studies in elderly patients with hypertension |
| Q44632357 | Lercanidipine vs lacidipine in isolated systolic hypertension |
| Q34644804 | Level of blood pressure control among hypertensive patients on follow-up in a regional referral hospital in Central Kenya |
| Q31103747 | Low-dose dextromethorphan, a NADPH oxidase inhibitor, reduces blood pressure and enhances vascular protection in experimental hypertension |
| Q47765260 | Managing Hypertension in Patients Aged 75 Years and Older |
| Q53710215 | Managing Hypertension in the Elderly: What is Different, What is the Same? |
| Q37229310 | Managing hypertension in the elderly in light of the changes during aging |
| Q34824900 | Managing the hypertensive patient with ischemic heart disease |
| Q24654799 | Manidipine-delapril combination in the management of hypertension |
| Q30967772 | Meta-analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data |
| Q30585374 | Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data |
| Q57142821 | Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials |
| Q73329127 | Mind the gap: pulse pressure, cardiovascular risk, and isolated systolic hypertension |
| Q31437386 | Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). |
| Q30976009 | Multivariate meta-analysis using individual participant data. |
| Q37381991 | New Generation Calcium Channel Blockers in Hypertensive Treatment |
| Q36107879 | Nitric oxide and sympathetic nerve activity in the control of blood pressure |
| Q82534363 | Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan |
| Q37053798 | Optimal drug treatment of systolic hypertension in the elderly |
| Q35210543 | Optimal management of hypertension in elderly patients |
| Q34327991 | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial |
| Q34268277 | Pharmacoeconomics of hypertension management: the place of combination therapy |
| Q73824328 | Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan |
| Q36931499 | Prevalence rates of self-care behaviors and related factors in a rural hypertension population: a questionnaire survey |
| Q35879105 | Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly |
| Q35818904 | Prevention and treatment of stroke in patients with hypertension |
| Q46782418 | Prevention of arteriosclerosis. Importance of the treatment of arterial hypertension |
| Q37104525 | Prevention of cardiovascular events by treating hypertension in older adults: an evidence-based approach |
| Q36106927 | Primary and secondary prevention of stroke by antihypertensive drug treatment |
| Q28080456 | Primary prevention: do the very elderly require a different approach? |
| Q42626145 | Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients |
| Q36283215 | Pulsatile and Steady-State Pressure Trends in Children: Is the Future Now?: Comment on the Paper by Zachariah and Kovacikova [Pulse 2014;2:57-62]. |
| Q36540301 | Pulse pressure and vascular risk in the elderly: associations and clinical implications |
| Q74265775 | Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study |
| Q73218242 | Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study |
| Q44396921 | Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly |
| Q42621178 | Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c |
| Q56970710 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document |
| Q34076195 | Recent advances in the management of hypertension in the elderly |
| Q49487797 | Recent changes in blood pressure levels, hypertension prevalence and treatment rates, and the rate of reaching target blood pressure in the elderly. |
| Q37890249 | Redefining blood pressure targets in high-risk patients?: lessons from coronary endpoints in recent randomized clinical trials |
| Q37677986 | Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis |
| Q38492295 | Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial |
| Q37199928 | Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension |
| Q73438211 | Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction. A 1-year clinical study comparing the effects of amlodipine and nifedipine retard on ambulatory blood pressure and left ventricular |
| Q37390022 | Results of a 14-Week, Multicenter, Prospective, Randomized, Open-Label, Noninferiority Clinical Trial Comparing the Antihypertensive Effect and Edema Incidence of Lacidipine and Amlodipine in Older Korean Patients with Mild-to-Moderate Hypertension |
| Q34983445 | Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension |
| Q44612188 | Risk of progression to hypertension in a rural Chinese women population with prehypertension and normal blood pressure |
| Q33897188 | Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials |
| Q48369245 | Robust reflections and radical thoughts: perspectives of a medical journal editor |
| Q38069195 | Role of dihydropyridinic calcium channel blockers in the management of hypertension. |
| Q61928734 | Selecting Optimum Antihypertensive Therapy |
| Q38071005 | Should we change the target blood pressure in diabetic patients? |
| Q33803000 | Systolic Blood Pressure Trajectory, Frailty, and All-Cause Mortality >80 Years of Age: Cohort Study Using Electronic Health Records |
| Q36069269 | Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study |
| Q42673025 | Systolic hypertension in older persons: complexities in clinical decision making |
| Q35407610 | Systolic hypertension: an increasing clinical challenge in Asia |
| Q36801094 | The 2014 hypertension guidelines: implications for patients and practitioners in Asia |
| Q36553794 | The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm. |
| Q35561932 | The Differences Between ACE Inhibitor‐Treated and Calcium Channel Blocker‐Treated Hypertensive Patients |
| Q35587336 | The Use of Calcium Antagonists in the Therapy of Hypertension in the Elderly |
| Q34317658 | The benefit of treating isolated systolic hypertension |
| Q34209022 | The economic impact of hypertension |
| Q38751502 | The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis |
| Q28487721 | The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials |
| Q44765714 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study |
| Q33939447 | The elderly patients on hemodialysis |
| Q37145649 | The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target |
| Q46154445 | The lower, the better? : fractional polynomials meta-regression of blood pressure reduction on stroke risk |
| Q37024404 | The metabolic syndrome in East Asians |
| Q35980993 | The paradigm has shifted to systolic blood pressure |
| Q35945719 | The role of existing and newer calcium channel blockers in the treatment of hypertension |
| Q55040066 | Thiazide diuretic-caused hyponatremia in the elderly hypertensive: will a bottle of Nepro a day keep hyponatremia and the doctor away? Study protocol for a proof-of-concept feasibility trial. |
| Q38988510 | Threshold and Target for Blood Pressure Lowering in the Elderly |
| Q73091312 | Translating worldwide calcium-channel blocker experience into clinical practice |
| Q34257837 | Treating hypertension in women of child-bearing age and during pregnancy |
| Q47611572 | Treatment and blood pressure control in isolated systolic hypertension vs diastolic hypertension in primary care |
| Q34028230 | Treatment of diabetic patients with hypertension |
| Q30245219 | Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets |
| Q35215068 | Treatment of hypertension in older patients: an updated look at the role of calcium antagonists |
| Q37748799 | Treatment of hypertension in the elderly in 2010 - a brief review |
| Q35905180 | Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists |
| Q79165287 | Trials in isolated systolic hypertension: An update |
| Q35170136 | Trials in isolated systolic hypertension: an update |
| Q35062333 | Uncontrolled hypertension as a risk for coronary artery disease: patient characteristics and the role of physician intervention |
| Q26778662 | Understanding and treating hypertension in diabetic populations |
| Q37890891 | Update on pathophysiology and treatment of hypertension in the elderly |
| Q46273828 | Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial |
| Q35839491 | Use of calcium channel antagonists for the treatment of hypertension in the elderly |
| Q37828060 | Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association |
| Q36050471 | Use of nifedipine in the treatment of hypertension |
| Q26864349 | What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations |
| Q35108207 | What is the most important component of blood pressure: systolic, diastolic or pulse pressure? |
| Q38676286 | What should the blood pressure be in patients with a prior ischemic stroke or a transient ischemic attack? |
| Q36540339 | Which components of the arterial pressure wave best predict risk? |
| Q64080242 | Why is the Chinese hypertension guideline necessary? |
| Q38237435 | Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update. |
| Q79362920 | [Cardiovascular pharmacotherapy in the aged] |
| Q77125683 | [Cerebral complications of hypertension in the elderly] |
| Q83300919 | [Hypertension in the elderly population] |
Search more.